HTX-201

N/A

Report date: 2026/01/28 20:01:42
NME

Base Information

Drug NameHTX-201
Drug Alias NameKHK-2455HTX-201
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIndoleamine 2,3-dioxygenase inhibitors
TargetsIndoleamine 2,3-dioxygenase
Therapy Area/IndicationsRejection of renal transplantationSolid tumoursCarcinoma, Transitional Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerlandFrance +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKyowa Hakko Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHornet Therapeutics Ltd
Inactive CompaniesKyowa Kirin Inc
Active IndicationsRejection of renal transplantationEpstein-Barr Virus Infections
Inactive IndicationsSolid tumoursCarcinoma, Transitional CellCarcinoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A